Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy.
Daniele G, Solis-Herrera C, Dardano A, Mari A, Tura A, Giusti L, Kurumthodathu JJ, Campi B, Saba A, Bianchi AM, Tregnaghi C, Egidi MF, Abdul-Ghani M, DeFronzo R, Del Prato S. Daniele G, et al. Among authors: mari a. Diabetologia. 2020 Nov;63(11):2423-2433. doi: 10.1007/s00125-020-05254-w. Epub 2020 Aug 22. Diabetologia. 2020. PMID: 32827269 Free PMC article. Clinical Trial.
Thiazolidinediones improve beta-cell function in type 2 diabetic patients.
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Gastaldelli A, et al. Among authors: mari a. Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E871-83. doi: 10.1152/ajpendo.00551.2006. Epub 2006 Nov 14. Am J Physiol Endocrinol Metab. 2007. PMID: 17106061 Free article. Clinical Trial.
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. Balas B, et al. Among authors: mari a. J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. doi: 10.1210/jc.2006-1882. Epub 2007 Jan 23. J Clin Endocrinol Metab. 2007. PMID: 17244786 Clinical Trial.
Insulin sensitivity and beta-cell function in the offspring of type 2 diabetic patients: impact of line of inheritance.
Natali A, Muscelli E, Mari A, Balkau B, Walker M, Tura A, Anderwald C, Golay A, Ferrannini E; Relationship between Insulin Sensitivity and Cardiovascular disease investigators. Natali A, et al. Among authors: mari a. J Clin Endocrinol Metab. 2010 Oct;95(10):4703-11. doi: 10.1210/jc.2009-2721. Epub 2010 Jul 21. J Clin Endocrinol Metab. 2010. PMID: 20660046 Clinical Trial.
Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance.
Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C, Abdul-Ghani MA. Kanat M, et al. Among authors: mari a. Diabetes. 2012 Feb;61(2):447-53. doi: 10.2337/db11-0995. Diabetes. 2012. PMID: 22275086 Free PMC article.
To characterize the defects in beta-cell function in subjects with impaired fasting glucose (IFG) and compare the results to impaired glucose tolerance (IGT) and normal glucose tolerance (NGT) subjects, beta-cell glucose sensitivity and rate sensitivity during the oral glucose to …
To characterize the defects in beta-cell function in subjects with impaired fasting glucose (IFG) and compare the results to impaired glucos …
The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
Van Raalte DH, van Genugten RE, Eliasson B, Möller-Goede DL, Mari A, Tura A, Wilson C, Fleck P, Taskinen MR, Smith U, Diamant M. Van Raalte DH, et al. Among authors: mari a. Eur J Endocrinol. 2014 Mar 8;170(4):565-74. doi: 10.1530/EJE-13-0639. Print 2014 Apr. Eur J Endocrinol. 2014. PMID: 24421302 Clinical Trial.
1,148 results